The US Food and Drug Administration (FDA) has cleared the TriLeap lower extremity anatomic plating system by Johnson & Johnson (J&J) company DePuy Synthes.
The clearance for US-based DePuy Synthes means the plating system can be used by surgeons to stabilise bones during bunionectomies, osteotomies, and fusions or fractures of the foot or ankle.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In a press release, J&J said DePuy Synthes expects to roll out the device in the US in 2024.
Bunions are one of the most common foot problems, affecting around one-third of older American adults. There are around 350,000 bunion surgeries performed in the US each year. Simple bunionectomies have higher-than-average failure rates.
The system will come with various plate options and procedure-specific implants with a range of screw diameters to cover multiple foot and ankle procedures.
The news follows another FDA clearance for DePuy Synthes after the agency cleared the company’s TriATLIS thoracolumbar implant system.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAnalysis by GlobalData placed the global orthopaedic market at $47.6bn in 2022. By 2030, the market is predicted to reach $60.2bn.
In April 2023, J&J agreed to pay almost $9bn to settle tens of thousands of lawsuits filed against the company claiming the use of its talcum powder caused cancer. US courts have blocked J&J’s attempted payout by assigning a subsidiary to manage the claims, meaning the lawsuits are still ongoing.
In September, the company underwent a transformation with its main departmental arms changing names and its logo undergoing a facelift, the famous cursive script being replaced with modernised branding.
